Genitourinary Cancers | Topics

 
Choosing a Combination Therapy for Renal Cell Carcinoma Before and After CLEAR Data
May 26, 2022

Brian Shimkus, MD, discusses how he chose between RCC combination therapies before CLEAR trial data, and how the data influences his decisions now.

Dose Reductions and Treatment Breaks on Lenvatinib Therapy
May 26, 2022

Dr Brian Shimkus describes how he doses lenvatinib for renal cell carcinoma treatment.

The Importance of Team-Based Management and Patient Communication
May 25, 2022

Robert Alter, MD, comments on the importance of team-based care and frequent, timely communication in managing patients with RCC.

Clinical Pearls on Tailoring Dosing Strategies in Metastatic Kidney Cancer
May 25, 2022

David Aggen, MD, PhD, identifies dosing strategies that may maximize treatment efficacy while minimizing toxicity in patients with kidney cancer.

Choosing Therapies for Patients with Advanced Renal Cell Carcinoma
May 19, 2022

A physician explains why he doesn’t believe there is a “typical” patient and why advanced RCC therapies must be tailored to each case.

Cytoreductive Nephrectomies for Renal Cell Carcinoma
May 19, 2022

Drs Thomas Hutson and Scott Tykodi explain when to consider a debulking surgery for patients with renal cell carcinoma.

Considerations for Patient-Focused, Shared Decision-Making in RCC
May 18, 2022

Chung-Han Lee, MD, PhD, delves into clinical and logistical factors that influence patient-focused, shared-decision making for those with metastatic RCC.

Patient-Specific Factors Impacting Treatment Choices in RCC
May 18, 2022

Mehmet Asim Bilen, MD, reviews patient-specific factors such as comorbidities, RCC histology, and metastatic status that may factor into treatment decision-making.

Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC
May 13, 2022

The panel summarizes unmet needs in frontline maintenance therapy for UC and comments on ongoing trials for novel treatment regimens.

Treatment Options After Progression on Frontline Maintenance Therapy
May 13, 2022

Petros Grivas, MD, PhD, revisits the patient profile and invites panel members to share recommended treatment options for patients with or without FGFR mutations, who progress after chemotherapy and maintenance avelumab.